Long-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms
Authors' conclusion
LT4/LT3 treatment was well-tolerated with no side effects and high QoL, but patients still experienced many symptoms.
Study context
- Population
- Hypothyroid patients who had previously initiated LT4/LT3 combination therapy for persistent hypothyroid symptoms; median age 56, therapy initiated 5.4 years ago
- Participants
- 66 patients
- Exposure
- T3 responders vs T3 non-responders
- T3 respondersn = 54
- T3 non-respondersn = 12reference
- Outcome
- QoL (ThyPRO) and hypothyroid symptoms (validated symptom score)
Methodological detailsreal-life, outpatient clinic
- Real-life
- Outpatient clinic
Main finding
As reported in the abstract
- Quality of life (QoL) in T3 responders comparable to the background population
- Symptom scores in T3 responders at the same levels as in Danish females with overt hypothyroidism
Observational data: associations, not effects.
Safety
- Thyoid stimulating hormone (TSH) <0.4 mU/L (overtreatment) in T3 responders
- 38%
Tolerability
- LT4/LT3 treatment well-tolerated with no side effects
Original publication
Long-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms. Eur Thyroid J. Published 21 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →